Iqvia Holdings Inc (NYSE:IQV) has been given an average recommendation of “Buy” by the twenty-two research firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $131.06.
A number of equities research analysts recently issued reports on IQV shares. Royal Bank of Canada reaffirmed a “$110.25” rating and issued a $128.00 target price on shares of Iqvia in a research note on Thursday, July 19th. ValuEngine upgraded Iqvia from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. SunTrust Banks increased their price target on Iqvia to $140.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Stifel Nicolaus increased their price target on Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Finally, Bank of America upgraded Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 price target for the company in a report on Wednesday, July 25th.
In other news, insider Kevin C. Knightly sold 9,216 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $126.46, for a total transaction of $1,165,455.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John G. Danhakl sold 221,900 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $126.63, for a total transaction of $28,099,197.00. The disclosure for this sale can be found here. Insiders have sold 601,586 shares of company stock worth $75,510,422 in the last ninety days. Corporate insiders own 6.00% of the company’s stock.
Shares of IQV traded down $1.64 during midday trading on Friday, reaching $124.05. 10,823 shares of the stock were exchanged, compared to its average volume of 1,481,199. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. Iqvia has a twelve month low of $91.57 and a twelve month high of $135.48. The stock has a market capitalization of $24.76 billion, a P/E ratio of 28.48, a price-to-earnings-growth ratio of 1.76 and a beta of 0.81.
Iqvia (NYSE:IQV) last posted its earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that Iqvia will post 5.13 EPS for the current fiscal year.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Read More: How a Put Option Works
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.